Intesa Sanpaolo reports progress in share buyback programme for annulment

Gian Maria Gros-Pietro Chairman of the Board of Directors of Intesa Sanpaolo Wikipedia
Gian Maria Gros-Pietro Chairman of the Board of Directors of Intesa Sanpaolo - Wikipedia
0Comments

Intesa Sanpaolo has reported the latest results of its ongoing share buyback programme, which aims to annul purchased shares. The bank stated that between 25 August and 29 August 2025, it acquired 44,758,684 of its own ordinary shares on Euronext Milan. This amount represents approximately 0.25% of the company’s total share capital.

The average purchase price for these transactions was €5.4469 per share, with a total expenditure of €243,796,713.21 over the period.

The buyback programme was first announced to the market on 26 May 2025 and began on 2 June 2025. Intesa Sanpaolo emphasized that Morgan Stanley Europe SE was appointed as an independent third-party intermediary to execute these transactions without involvement from the Intesa Sanpaolo Group.

The purchases are part of a broader plan by Intesa Sanpaolo to reduce its outstanding shares through annulment.

A spokesperson for Intesa Sanpaolo commented: “With reference to the execution of the programme of purchase of own shares for annulment (buyback), which was disclosed to the market on 26 May 2025 and launched on 2 June 2025, Intesa Sanpaolo, pursuant to applicable regulations, communicates that – on the basis of information provided by Morgan Stanley Europe SE, the third-party intermediary appointed to execute the programme in full independence and without any involvement of the Intesa Sanpaolo Group – from 25 August to 29 August 2025 the Bank executed the purchase transactions summarised in the table below on the regulated market Euronext Milan managed by Borsa Italiana.”



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.